1. Catalogs
  2. Spineart
  3. JULIET ® OL
video corpo

JULIET ® OL
1 /2Pages

JULIET ® OL

JULIET ® OL
1 /2Pages

Catalog excerpts

JULIET ® OL-1

JULIET®OL Study #52001 The JULIET®OL, lumbar intersomatic poly-ether-ether-ketone cage used for symptomatic degenerative disc diseases treatment by arthrodesis. Safety and effectiveness evaluation after two years follow-up Investigator initiated study FDA approved for this indication Region: France Status: Completed Post CE-Marking Follow-up Study submitted to HAS (FR) Primary Objectives:  Safety of JULIET®OL, lumbar inter-somatic cage, evaluation based on all events observed (controls, investigations, hospitalizations, interventions) during 2 year follow-up after arthrodesis.  Overall performance of JULIET®OL, evaluated at the end of 2 years follow-up period, as a composite primary endpoint, based on data at last visit: - Incidence and seriousness of implant related complications - Absence of lumbar and radicular pain - Absence of neurologic disorders (sensitive and/or motor) - Fusion status - Patient satisfaction - Global prognostic Secondary objectives: Early qualitative effectiveness evaluation, at 2 months after surgery for lumbar arthrodesis using JULIET®OL:  Overall success evaluated by Stauffer criteria: - Pain relief - Time after surgery for getting back to work - Diminution of physical activities - Pain medication  Functional improvement evaluated by Lassale criteria: - Claudication - Radicular pain (at rest and at effort) - Lumbar pain - Neurologic disorders - Pain medication - Kinesitherapy - Time after surgery for getting back to normal life  Radiologic criteria: - Implant positioning - Radicular compression Indication - condition: Symptomatic lumbar disc degenerative disease Study type: Observational, cohort, retrospective analysis Patients enrolled: 27 Primary outcomes: • Incidence of SAE and AE implant related • Absence of lumbar and radicular pain • Absence of neurologic disorders (sensitive and/or moto

 Open the catalog to page 1
JULIET ® OL-2

• Patient satisfaction • Global prognostic Secondary outcomes: • Changes in back and leg pain (compared to preoperative status) • Changes in physical activities capacity (compared to preoperative status) • Pain medication (drug's category and frequency) • Radicular pain (at rest and at effort) • Neurologic disorders (motor and/or sensitive) • Time after surgery for getting back to work • Time after surgery for getting back to normal life • Implant positioning • Radicular compression

 Open the catalog to page 2

All Spineart catalogs and technical brochures

  1. JULIET®AN

    1  Page

  2. TRYPTIK ® CA

    2  Pages

  3. JULIET® PO

    2  Pages

  4. BAGUERA ® C

    1  Page

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.